Print

U.S. Granted Patent 8,088,385 B2 Strengthens Advanced Cardiac Therapeutics' Anti-Cancer Product Portfolio  
4/3/2012 9:48:51 AM

LOUISVILLE, Ky., April 3, 2012 (GLOBE NEWSWIRE) -- Advanced Cancer Therapeutics (ACT), a privately held company dedicated to bringing new anti-cancer therapies to market, today announced that it has been granted U.S. Patent 8,088,385 B2 titled "PFKFB3 inhibitor for the treatment of a Proliferative Cancer" by the United States Patent Office. ACT is the exclusive licensee to this issued patent that was initially filed by the University of Louisville Research Foundation.
//-->